Akston Biosciences Ends Vaccine Partnership with Stelis, Continues to Advance COVID Universal Booster EUA
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today it has ended its AKS-452 licensing, manufacturing, and commercialization agreement with Stelis Biopharma Limited, an arm of Strides Pharma Science Ltd.
Todd Zion Akston Biosciences Johnson Janssen Akston Biosciences Corporation Strides Pharma Science Ltd Merck Co
Source: businesswireindia.com